Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L T Bacheler

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Journal of Virology|October 1, 1980
Molecular cloning of unintegrated and a portion of integrated moloney murine leukemia viral DNA in bacteriophage lambdaA J Berns, M H Lai, R A Bosselman, et al.
Science (New York, N.Y.)|January 21, 1994
Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitorsP Y Lam, P K Jadhav, C J Eyermann, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2001
4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitorsA J Cocuzza, D R Chidester, B C Cordova, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 1999
The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitorsM Patel, R F Kaltenbach, D A Nugiel, et al.
Journal of Medicinal Chemistry|May 24, 1996
Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitorsD A Nugiel, K Jacobs, R F Kaltenbach, et al.
Journal of Medicinal Chemistry|June 19, 1998
Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analoguesG V De Lucca, U T Kim, J Liang, et al.
Antimicrobial Agents and Chemotherapy|August 22, 2000
Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapyL T Bacheler, E D Anton, P Kudish, et al.
Antimicrobial Agents and Chemotherapy|December 3, 1999
Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1J W Corbett, S S Ko, J D Rodgers, et al.
Journal of Medicinal Chemistry|May 9, 1997
Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysisD A Nugiel, K Jacobs, L Cornelius, et al.
Journal of Medicinal Chemistry|May 23, 1998
Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studiesP K Jadhav, F J Woerner, P Y Lam, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Journal of Virology|October 1, 1980
Molecular cloning of unintegrated and a portion of integrated moloney murine leukemia viral DNA in bacteriophage lambdaA J Berns, M H Lai, R A Bosselman, et al.
Science (New York, N.Y.)|January 21, 1994
Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitorsP Y Lam, P K Jadhav, C J Eyermann, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2001
4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitorsA J Cocuzza, D R Chidester, B C Cordova, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 1999
The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitorsM Patel, R F Kaltenbach, D A Nugiel, et al.
Journal of Medicinal Chemistry|May 24, 1996
Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitorsD A Nugiel, K Jacobs, R F Kaltenbach, et al.
Journal of Medicinal Chemistry|June 19, 1998
Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analoguesG V De Lucca, U T Kim, J Liang, et al.
Antimicrobial Agents and Chemotherapy|August 22, 2000
Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapyL T Bacheler, E D Anton, P Kudish, et al.
Antimicrobial Agents and Chemotherapy|December 3, 1999
Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1J W Corbett, S S Ko, J D Rodgers, et al.
Journal of Medicinal Chemistry|May 9, 1997
Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysisD A Nugiel, K Jacobs, L Cornelius, et al.
Journal of Medicinal Chemistry|May 23, 1998
Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studiesP K Jadhav, F J Woerner, P Y Lam, et al.
Pageof 4